Abstract
We conducted a multicenter, randomized, open-label, ascending dose study to investigate the efficacy and safety of combination therapy using the calcium channel blocker azelnidipine and angiotensin-converting enzyme (ACE) inhibitor temocapril in hypertensive diabetics. Patients received monotherapy with 8 mg azelnidipine (group A, n=112) or 2 mg temocapril (group T, n=111) for 4 weeks. If the target blood pressure (<130/80 mmHg) was not achieved, doses were doubled. If it was still not achieved, both drugs were coadministered at week 8, and, if needed, another antihypertensive drug was added after week 16. The treatment period was 52 weeks. Blood pressure was decreased significantly beginning at week 8 (p<0.0001 in both groups), and the systolic and diastolic blood pressure at the end of the treatment period was 128.2±11.1/76.4±8.1 mmHg. Overall, 53.8% (113/210) of patients achieved the target blood pressure by the end of the study. The effect during the monotherapy period (through week 8) was greater in group A than in group T (systolic, p=0.0475; diastolic, p=0.0001). Laboratory tests showed significant decreases in the urine albumin: creatinine ratio (p=0.0006), high-sensitivity C-reactive protein concentration (p=0.0073), and urine 8-isoprostane concentration (p=0.0215) at the end of the treatment period, as compared with baseline values. No adverse events caused safety problems. In conclusion, combination therapy using azelnidipine and temocapril is an effective treatment for hypertensive diabetics.
Similar content being viewed by others
Article PDF
References
Chobanian AV, Bakris GL, Black HR, et al: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Arauz-Pancheco C, Parrott MA, Raskin P, American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26 ( Suppl 1): S80–S82.
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 ( Suppl 1): S1–S266.
Tatti P, Pahor M, Byington RP, et al: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
Katayama S, Kawamori R, Shimamoto K, Ogihara T, Kikkawa R : Collections and analysis of basic data for development of ‘Therapeutic guideline for management of diabetic hypertension in Japan.’ Ther Res 1998; 19: 2949–2968 ( in Japanese).
Hansson L, Zanchetti A, Carruthers SG, et al: HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R : Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601–605.
Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M : Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143–151.
Singer GM, Izhar M, Black HR : Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40: 464–469.
Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T : Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201–208.
Naito Y, Shimozawa M, Manabe H, et al: Anti-oxidative properties of a new calcium channel blocker azelnidipine. Prog Med 2004; 24: 2676–2681 ( in Japanese).
Horiuchi M : Protective effects of azelnidipine and their enhancement by the combination with angiotensin II type 1 receptor blockers. Prog Med 2004; 24: 2682–2687 ( in Japanese).
Hata T : Endothelial dysfunction in essential hypertension and temocapril. Prog Med 1999; 19: 1123–1128 ( in Japanese).
Muso E, Takeda T, Suyama K : Specific renoprotective effect of temocapril (TEM), an ACE inhibitor with biliary excretion, in human and animal model of renal damages with massive proteinuria. Prog Med 1999; 19: 1138–1143 ( in Japanese).
Fujimoto S, Sato M, Komai N, Kashihara N : Effects of azelnidipine on renal microcirculation. Prog Med 2004; 24: 2670–2675 ( in Japanese).
Nakamura T, Sugaya T, Kawagoe Y, et al: Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321–326.
Fliser D, Buchholz K, Haller H, European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103–1107.
Fliser D, Wagner KK, Loos A, Tsikas D, Haller H : Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135–1140.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Katayama, S., Kawamori, R., Iwamoto, Y. et al. In Half of Hypertensive Diabetics, Co-Administration of a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor Achieved a Target Blood Pressure of <130/80 mmHg: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes (ATTEST) Study. Hypertens Res 31, 1499–1508 (2008). https://doi.org/10.1291/hypres.31.1499
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1499
Keywords
This article is cited by
-
Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review
Cardiology and Therapy (2022)
-
A case of complete atrioventricular block with extremely high blood concentration of azelnidipine
Journal of Pharmaceutical Health Care and Sciences (2021)
-
Evidence-based practice guideline for the treatment for diabetes in Japan 2013
Diabetology International (2015)
-
Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG)
Cardiovascular Drugs and Therapy (2011)